Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
Wolfe Research downgraded Stryker (SYK) to Peer Perform, citing a difficult second-half outlook after a March cyber disruption and noting the June quarter did not fully catch up. Wolfe said Stryker’s guidance implies 54% of revenue in 2H. Wolfe upgraded Abbott (ABT) to Outperform with a $130 target, citing better 2027 catalysts.
How this was made
The 30-second read
Why it matters
For SYK, the downgrade centers on second-half execution risk and a negative near-term estimate skew. For ABT, the upgrade centers on a stronger 2027 setup, including electrophysiology launch progress, Libre growth recovery, and cost-synergy realization from the Exact Sciences deal.
Market read
This is a peer-relative repricing catalyst for two med-tech names, driven by execution and forward growth assumptions rather than new company filings or trial results.
What to watch
No new operational datapoint is provided beyond the cyber disruption context and forward setup; traders may need to wait for company-specific updates (guidance, product milestones, reimbursement) to confirm the thesis.
Background
Wolfe Research issued two rating changes in large-cap medical devices, downgrading Stryker and upgrading Abbott.
Ticker impact
Wolfe downgrades Stryker to Peer Perform, citing a demanding second-half setup after the March cyber disruption and negative estimate skew.
Bias toward downside or underperformance versus peers until de-risking improves.
The article provides a clear rating cut and specific thesis (2H burden, slower growth), which typically pressures near-term sentiment.
Wolfe upgrades Abbott to Outperform with a $130 price target, pointing to better 2027 setup and multiple device and cost-synergy catalysts.
Bias toward relative outperformance versus med-tech peers on upgrade-driven sentiment.
The article includes an explicit upgrade, target, and enumerated catalysts, which are actionable for positioning over days to weeks.
Market effects
Signals a bifurcated med-tech tape, with device growth and execution risk being repriced across large-cap peers.
Primarily US large-cap med-tech sentiment; limited direct regional spillover implied.
Could influence global med-tech relative-value positioning, but no cross-border deal or regulatory action is cited.
Counterpoint
The article’s core claims are estimate and execution framing; valuation is described as “fair” for SYK, suggesting limited downside if investors already priced the risk.
Key entities
- companyStryker
Downgraded by Wolfe to Peer Perform due to second-half de-risking concerns after a March cyber disruption.
- companyAbbott Laboratories
Upgraded by Wolfe to Outperform with a $130 price target, citing multiple 2027 catalysts and under-guided synergies.
- analyst_firmWolfe Research
Issued the rating changes and provided the thesis for each stock.
